SCHEMBL1493046

SCHEMBL1493046

O=P(O)(O)OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O

nearest known ligand 0.52

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ADSS2 P30520 2/20 0.52
FBP1 P09467 1/20 0.51
P2RY14 Q15391 2/20 0.47
IGF2R P11717 4/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
AMDHD2 Q9Y303 1/20 0.38
PGD P52209 1/20 0.38
P2RY2 P41231 1/20 0.37
P2RY4 P51582 1/20 0.37
DNPH1 O43598 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16550 1.00 ADSS2 (0.52) ADSS2FBP1P2RY14IGF2RMEN1
SCHEMBL135311 1.00 ADSS2 (0.52) ADSS2FBP1P2RY14IGF2RMEN1
SCHEMBL850081 1.00 ADSS2 (0.52) ADSS2FBP1P2RY14IGF2RMEN1
SCHEMBL2591882 1.00 ADSS2 (0.52) ADSS2FBP1P2RY14IGF2RMEN1
SCHEMBL31153353 1.00 ADSS2 (0.52) ADSS2FBP1P2RY14IGF2RMEN1
SCHEMBL8056 1.00 ADSS2 (0.52) ADSS2FBP1P2RY14IGF2RMEN1
SCHEMBL1532483 1.00 ADSS2 (0.52) ADSS2FBP1P2RY14IGF2RMEN1
SCHEMBL9736981 1.00 ADSS2 (0.52) ADSS2FBP1P2RY14IGF2RMEN1
SCHEMBL5981501 0.98 ADSS2 (0.51) ADSS2FBP1P2RY14IGF2RMEN1
Water SCHEMBL5614144 0.98 ADSS2 (0.51) ADSS2FBP1P2RY14IGF2RMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023081455-A2 IMMUNE CELLS EXPRESSING GLUCOSE TRANSPORTER 5 (GLUTS) AND COMPOSITIONS AND METHODS INCLUDING THE SAME MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2023-05-11 WO disclosed
CN-115112877-A Serum metabolic marker and application thereof in evaluating stability of intracranial arterial plaque 河北医科大学第二医院 2022-09-27 CN disclosed
EP-3927816-A1 DEGRADATION PATHWAY FOR PENTOSE AND HEXOSE SUGARS Braskem S.A. (BR) 2021-12-29 EP disclosed
EP-3908663-A1 MICROORGANISMS AND METHODS FOR THE PRODUCTION OF OXYGENATED COMPOUNDS FROM HEXOSES Braskem S.A. (BR) 2021-11-17 EP disclosed
CN-105255804-B A kind of catalysis methanol prepares Recombinant organism of isoprene and the preparation method and application thereof 中国科学院青岛生物能源与过程研究所 2018-09-18 CN disclosed
CN-104619835-B Ketol acid reductoisomerase enzymes and methods of use thereof 布特马斯先进生物燃料有限责任公司 2018-06-19 CN disclosed
CN-103827304-B Host cell and method for isobutanol production 布特马斯先进生物燃料有限责任公司 2018-04-17 CN disclosed
CN-104039974-B The production of the isoprenoid that S-acetyl-coenzyme-A is derivative 阿迈瑞斯公司 2016-10-12 CN disclosed
CN-105255804-A Escherichia coli genetically engineered bacteria for preparing isoprene through catalytic methanol and preparation method and application of escherichia coli genetically engineered bacteria QINGDAO INST BIOENERGY & BIOPROCESS TECHNOLOGY CAS 2016-01-20 CN disclosed
CN-105189772-A Use of phosphoketolase and phosphotransacetylase for production of acetyl-coenzyme a derived compounds AMYRIS INC 2015-12-23 CN disclosed
CN-104039974-A Production Of Acetyl-coenzyme A Derived Isoprenoids AMYRIS INC 2014-09-10 CN disclosed
WO-2014100722-A9 CELL-FREE SYSTEM FOR CONVERTING METHANE INTO FUEL, PYRUVATE OR ISOBUTANOL GREENLIGHT BIOSCIENCES, INC. (US) 2014-07-31 WO disclosed
WO-2014100722-A1 CELL-FREE SYSTEM FOR CONVERTING METHANE INTO FUEL, PYRUVATE OR ISOBUTANOL GREENLIGHT BIOSCIENCES, INC. (US) 2014-06-26 WO disclosed
CN-103827304-A Host cells and methods for production of isobutanol BUTAMAX TM ADVANCED BIOFUELS 2014-05-28 CN disclosed
CN-103443271-A Isoprene synthase variants for increased isoprene production DANISCO US INC 2013-12-11 CN disclosed
CN-101472604-B Viable non-toxic gram negative bacteria RES CORP TECHNOLOGIES INC 2013-11-06 CN disclosed
CN-101775421-B Method for preparing 1-deoxy-D-xylulose 5-phosphate by chemical method and enzymatic method UNIV NORTHWESTERN 2013-11-06 CN disclosed
US-20120258050-A1 13C-MR DETECTION USING HYPERPOLARISED 13C-FRUCTOSE GE HEALTHCARE LIMITED (GB) 2012-10-11 US disclosed
EP-2476009-A1 13C-MR DETECTION USING HYPERPOLARISED 13C-FRUCTOSE GE Healthcare UK Limited (GB) 2012-07-18 EP disclosed
WO-2011029854-A1 13C-MR DETECTION USING HYPERPOLARISED 13C-FRUCTOSE GE HEALTHCARE LIMITED (GB) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120258050-A1 13C-MR DETECTION USING HYPERPOLARISED 13C-FRUCTOSE FBP1, ALDOA, HK2 ADSS2 2573/4885FBP1 1/4885P2RY14 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.